In: Chapman, Michael W
Marketed by Meitheal Pharmaceuticals Inc., this product is identified by NDC 71288-300 and is authorized under FDA application ANDA214316
Some effects (e.g., short-term cognitive performance with methylene blue, mild energy effects with NAD+) may be noticed within hours to days
This process, called lipolysis, is enhanced when these nutrients are available in optimal amounts
Any condition affecting the gastrointestinal tract, such as autoimmune gastritis (which can lead to pernicious anaemia), celiac disease, Crohns disease, or surgical procedures like gastric bypass surgery, gastrectomy or terminal ileal resection, can impair the absorption of B12, and increases the chance of developing vitamin B12 deficiency
Not all payers cover every formulation under J1815, and payer-specific drug formularies may apply